Abstract
CDC25 dual specificity phosphatases activate the cyclin-dependent kinase complexes, allowing timely ordered progression through out the different phases of the eukaryotic cell cycle. In humans, there are three genes coding for the CDC25A, B and C proteins with both different and redundant specificities and regulations. The CDC25A member of this family acts during the G1 phase and at the G1/S transition by activating the CDK2/cyclin E and CDK2/cyclin A complexes, a function apparently not shared by the other members. In consequence, CDC25A is submitted to extra-cellular signals-dependent regulations involving in particular mitogenic signal transducers, and leading to modifications of its stability, its localization or its activity. In addition, CDC25A is up-regulated in various cancers, and the molecular mechanisms leading to this up-regulation are far from being understood. In this review, we will synthesize the current knowledge about CDC25A molecular regulations, and try to integrate these data in the cell proliferation and apoptotic functions described for the protein.
Keywords: CDC25A phosphatase, cell cycle, proliferation, apoptosis, G1/S transition, oncogenesis
Anti-Cancer Agents in Medicinal Chemistry
Title: CDC25A: A Rebel Within the CDC25 Phosphatases Family?
Volume: 8 Issue: 8
Author(s): Anne Fernandez-Vidal, Anne Mazars and Stephane Manenti
Affiliation:
Keywords: CDC25A phosphatase, cell cycle, proliferation, apoptosis, G1/S transition, oncogenesis
Abstract: CDC25 dual specificity phosphatases activate the cyclin-dependent kinase complexes, allowing timely ordered progression through out the different phases of the eukaryotic cell cycle. In humans, there are three genes coding for the CDC25A, B and C proteins with both different and redundant specificities and regulations. The CDC25A member of this family acts during the G1 phase and at the G1/S transition by activating the CDK2/cyclin E and CDK2/cyclin A complexes, a function apparently not shared by the other members. In consequence, CDC25A is submitted to extra-cellular signals-dependent regulations involving in particular mitogenic signal transducers, and leading to modifications of its stability, its localization or its activity. In addition, CDC25A is up-regulated in various cancers, and the molecular mechanisms leading to this up-regulation are far from being understood. In this review, we will synthesize the current knowledge about CDC25A molecular regulations, and try to integrate these data in the cell proliferation and apoptotic functions described for the protein.
Export Options
About this article
Cite this article as:
Fernandez-Vidal Anne, Mazars Anne and Manenti Stephane, CDC25A: A Rebel Within the CDC25 Phosphatases Family?, Anti-Cancer Agents in Medicinal Chemistry 2008; 8 (8) . https://dx.doi.org/10.2174/187152008786847684
DOI https://dx.doi.org/10.2174/187152008786847684 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Colorectal Cancer Classification and Survival Analysis Based on an Integrated RNA and DNA Molecular Signature
Current Bioinformatics Targeted Cancer Therapeutics: Biosynthetic and Energetic Pathways Characterized by Metabolomics and the Interplay with Key Cancer Regulatory Factors
Current Pharmaceutical Design Recent Development of Peptide Drugs and Advance on Theory and Methodology of Peptide Inhibitor Design
Medicinal Chemistry Peptides for Tumour Therapy and Diagnosis: Current Status and Future Directions
Current Medicinal Chemistry Interlinking of Hypoxia and Estrogen in Thyroid Cancer Progression
Current Medicinal Chemistry Targeting Opioid and Neurokinin-1 Receptors to Treat Alcoholism
Current Medicinal Chemistry Salen Mn Complexes are Superoxide Dismutase/Catalase Mimetics that Protect the Mitochondria
Current Inorganic Chemistry (Discontinued) Role of Cardiolipin in Mitochondrial Diseases and Apoptosis
Current Medicinal Chemistry Role of the Akt Pathway in Prostate Cancer
Current Cancer Drug Targets Imaging Methods in Gene Therapy of Cancer
Current Gene Therapy Peptidyl Prolyl Isomerase, Pin1 is a Potential Target for Enhancing the Therapeutic Efficacy of Etoposide
Current Cancer Drug Targets Cannabinoids: Occurrence and Medicinal Chemistry
Current Medicinal Chemistry Peroxisome Proliferator Activated Receptor α Ligands as Anticancer Drugs Targeting Mitochondrial Metabolism
Current Pharmaceutical Biotechnology Cyclization in Opioid Peptides
Current Drug Targets Metabotropic Glutamate Receptors: A Review on Prospectives and Therapeutic Aspects
Mini-Reviews in Medicinal Chemistry Characterization of Breast Lesions by Magnetic Resonance Imaging (MRI) and Spectroscopy (MRS)
Current Medical Imaging Modulation of Ischemic Brain Injury and Neuroinflammation by Adenosine A2A Receptors
Current Pharmaceutical Design Design, Synthesis, and Transport Potential of a New Family of Nonionic Amphiphilic Dendro-calix[4]arene
Current Organic Chemistry Tumor Escape from Immune Response: Mechanisms and Targets of Activity
Current Drug Targets MATra - Magnet Assisted Transfection: Combining Nanotechnology and Magnetic Forces to Improve Intracellular Delivery of Nucleic Acids
Current Pharmaceutical Biotechnology